ABSTRACT
Glipizide is an antidiabetic drug that belongs to a class of medication known as sulfonylureas. It is considered one of the highly prescribed antidiabetic drugs for the treatment of type II diabetes in patients following a kidney transplant. It lowers blood glucose levels by causing the release of insulin from ß-cells in the pancreas. Its main metabolizing pathway is through the liver. It has several adverse effects, which range from an upset stomach to glipizide-induced haemolytic anaemia and hypoglycaemia. These adverse effects may be spontaneous, or they could have a genetic cause. The present study aimed to assess and document the incidence of glipizide-induced adverse reactions among patients prescribed the drug. The present retrospective case-control study used the electronic medical records of patients prescribed glipizide for the past 3 years. These records were reviewed to extract and document cases and/or signs of glipizide-induced adverse reactions. The results revealed that the incidence of adverse effects was higher among female patients (odds ratio, 2.40, P<0.001). Moreover, the results revealed that the likelihood of developing adverse drug reactions among patients <40 years of age was higher than in older patients (P>0.05). The outcomes of the present study are expected to prompt future studies to take sex and age into consideration, in an aim to improve treatment outcomes, reduce adverse events and decrease the burden of unnecessary costs for healthcare systems. Recommendations also include genetic screening prior to administering the medication, educating the patients and caregivers on the possibility of adverse drug reactions, and routine follow-up. This issue is of utmost importance to achieve the optimal outcomes with the minimal detrimental effects.
ABSTRACT
Objective:To investigate the effectiveness and safety of docetaxel combined with cisplatin in the second-line treatment of advanced non-small cell lung cancer in older adult patients.Methods:120 older adult patients with advanced non-small cell lung cancer who received second-line treatment in Jiaozhou People's Hospital from January 2017 to December 2019 were included in this study. They were randomly assigned to undergo treatment with docetaxel (control group, n = 60) or docetaxel + cisplatin (observation group, n = 60). Clinical efficacy and complications were compared between the two groups. Results:After chemotherapy, short-term total response rate was significantly higher in the observation group than in the control group [70.00% (42/60) vs. 33.33% (20/60), χ2 = 16.15, P < 0.05]. Serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19-fragment CYFRA21-1 were (22.57 ± 3.22) μg/L, (48.61 ± 5.42) U/mL, (10.61 ± 1.64) μg/L, respectively in the observation group, which were significantly lower than those in the control group [(35.52 ± 4.46) μg/L, (69.64 ± 7.75) U/mL, (14.26 ± 1.95) μg/L, t = 18.23, 17.22, 11.09, all P < 0.001]. The percentages of CD 3+ and CD 4+ cells were (78.31 ± 8.09)% and (48.63 ± 5.74)%, respectively in the observation group, which were significantly higher than those in the control group [(69.58 ± 7.26)%, (39.82 ± 4.25)%, t = -6.22, -9.55, both P < 0.001]. The percentage of CD 8+ was significantly lower in the observation group than in the control group [(22.64 ± 3.82)% vs. (26.77 ± 4.01)%, t = 5.77, P < 0.001). The 1-year survival was significantly higher in the observation group than in the control group ( χ2 = 4.05, P < 0.05). There was no significant difference in the incidence of adverse reactions during chemotherapy between the two groups ( P > 0.05). Conclusion:Docetaxel combined with cisplatin is highly effective on advanced non-small cell lung cancer in older adult patients. The combined therapy can decrease serum tumor marker levels, improve immune function, and increase 1-year survival rate. It is safe and provides reliable efficacy and thereby is worthy of clinical promotion.
ABSTRACT
OBJECTIVE：To explore the regularity and characteristics of adverse drug reactions （ADR）induced by alectinib ， and to provide reference for rational drug use in clinic. METHODS ：Retrieved from CNKI ，Wanfang database ，VIP，PubMed， Web of Science and Embase database during the inception to Mar. 1st，2021，case reports of alectinib-induced ADR were collected ， summarized and analyzed with descriptive statistical analysis method in terms of general information ，occurrence time of ADR ， involved organ/system ，clinical manifestations ，treatment and outcome ，etc. RESULTS ：A total of 17 literatures were included ， involving 17 patients. Among them ，4 cases（23.53％）were males ，and 13 cases（76.47％）were females. The mean age of the patients was （61.82±14.18）years old. The patients were from 5 countries/regions，among which America took the largest ratio （41.18％）. Most ADR occurred within 30 days（52.94％）after therapy. ADR mainly involved skin and its appendants （35.29％）， followed by respiratory system （23.53％），urinary system （11.76％），cardiovascular system （11.76％），gastrointestinal system （11.76％）and blood system （5.87％）；hair loss ，pancreatitis and duodenal perforation belonged to ADRs not recorded in the drug instructions. After 17 patients suffered from ADR ，2 patients still continued to use aletinib ，while 15 patients withdrew aletinib and some patients received symptomatic and supportive treatment ，and their symptoms improved. Among them ，10 patients restarted aletinib treatment after their symptoms improved ，and 8 patients did not suffered from ADR again. CONCLUSIONS ：Female patients and patients over 50 years old are more likely to suffer from ADR after using aletinib ，and most of ADR occur within 1 month after treatment. ADR involves many organs/systems ，mainly skin and its appendants. Special attention should be paid to ADR such as hair loss ，pancreatitis and duodenal perforation.